11 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 17 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 11, Active not recruiting 2, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow tepotinib: new trials by email Literature Review of tepotinib trials Research Report on tepotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer Tepotinib, Ivonescimab - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-05-27 | 2026-09-16 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Amivantamab, Tepotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2024-06-18 | 2026-09-11 |
| POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC Tepotinib, Pembrolizumab - Advanced Cancer, Non Small Cell Lung Cancer | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 19 | 2023-05-03 | 2026-04-24 |
| A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors tepotinib, tepotinib plus osimertinib - Brain Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2023-02-27 | 2024-04-17 | |
| CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC Tepotinib - Advanced Non-Small Cell Lung Cancer With MET Mutations | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 2 | 2022-05-25 | 2023-10-18 |
| Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma Tepotinib plus paclitaxel - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 / Phase 2 | Unknown | Hallym University Medical Center | 42 | 2022-03-01 | 2022-07-05 |
| Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants Tepotinib (HydroChloride hydrate), Itraconazole - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 18 | 2022-01-21 | 2024-02-20 |
| Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants Tepotinib, Carbamazepine - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 18 | 2021-12-15 | 2024-03-08 |
| Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib Tepotinib 100 mg, Tepotinib 250 mg - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 18 | 2019-10-17 | 2023-11-08 |
| Effect of Tepotinib on PK of CYP3A Substrate Midazolam Midazolam, Tepotinib - Healthy | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 12 | 2018-08-20 | 2023-07-28 |
| Tepotinib Hepatic Impairment Trial Tepotinib - Hepatic Impairment | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 18 | 2018-06-13 | 2024-08-12 |
| Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate Dabigatran Etexilate, Tepotinib - Healthy | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 20 | 2018-05-17 | 2023-08-07 |
| Effect of a Proton Pump Inhibitor on the PK of Tepotinib Tepotinib, Omeprazole - Healthy | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 12 | 2018-05-14 | 2023-07-28 |
| c-Met Second-Line Hepatocellular Carcinoma Tepotinib - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 66 | 2014-05-18 | 2022-08-24 |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 117 | 2014-01-06 | 2022-08-24 |
| Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) Tepotinib, Gefitinib, Pemetrexed - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 88 | 2013-12-23 | 2022-11-08 |
| First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors MSC2156119J - Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available | Phase 1 | Completed | EMD Serono | 149 | 2009-11-30 | 2022-08-24 |
Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Hepatocellular (2) · Brain Neoplasms (1) · Lung Neoplasms (1) · Stomach Neoplasms (1)
Merck KGaA, Darmstadt, Germany (6) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (3) · M.D. Anderson Cancer Center (2) · Criterium, Inc. (1) · EMD Serono (1) · EMD Serono Research & Development Institute, Inc. (1) · Hallym University Medical Center (1) · Institute of Cancer Research, United Kingdom (1) · Memorial Sloan Kettering Cancer Center (1)
Germany (7) · United States (5) · South Korea (3) · China (2) · Taiwan (2) · Italy (1) · Malaysia (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Anna Minchom, MD (1) · Barbara O'Brien, MD (1) · Dae Young Zang, Dr (1) · David R Camidge, MD, PhD (1) · Paul Paik, MD (1) · Tejas Patil, MD (1) · Xiuning Le, MD,PHD (1)
PMID 35771259, PMID 37415001, PMID 40679917, PMID 31822497, PMID 32479794, PMID 33824476, PMID 33972742, PMID 36101520, PMID 40880848
2017 (3), 2016 (1), 2019 (1)